Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

2013/07/01 by Elisabet I. Nielsen, Lena E. Friberg · 332 citations
Biochemistry, Genetics and Molecular Biology · Engineering · Medicine · #Antibiotic Resistance in Bacteria #Antibiotics #Antibiotics Pharmacokinetics and Efficacy #Biochemical engineering #Biology #Dosing #Drug #Drug Transport and Resistance Mechanisms #Drug development #Engineering #Intensive care medicine #Medicine #Microbiology #Pharmacodynamics #Pharmacokinetics #Pharmacology

paper · doi:10.1124/pr.111.005769

published in Pharmacological Reviews 65(3), 1053-1090 (American Society for Pharmacology and Experimental Therapeutics)

openalex publication_date 2013/07/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Citations

• Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
• Diagnosing Model Diagnostics

Cited by

• Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
• Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistant Acinetobacter baumannii at clinically achievable concentrations
• A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
• Simulation-based evaluation of the impact of dose fractionation study design on antibiotic PKPD analyses
• Amoxicillin—current use in swine medicine
• Failure and Success in Single-Drug Control of Antimicrobial Resistance
• The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. [europepmc]
• Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. [europepmc]
• Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling. [europepmc]
• Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction. [europepmc]
• Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. [europepmc]
• Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation. [europepmc]
• Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. [europepmc]
• A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. [europepmc]
• A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis. [europepmc]
• An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. [europepmc]
• Delivering precision antimicrobial therapy through closed-loop control systems. [europepmc]
• A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions. [europepmc]
• En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach. [europepmc]
• PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs. [europepmc]
• Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. [europepmc]
• Avibactam Pharmacokinetic/Pharmacodynamic Targets. [europepmc]
• Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. [europepmc]
• Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. [europepmc]
• Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. [europepmc]
• Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. [europepmc]
• Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens. [europepmc]
• The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials. [europepmc]
• Design principles of collateral sensitivity-based dosing strategies. [europepmc]
• Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. [europepmc]
• Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models. [europepmc]